EN 简
About CARsgen®
We focus on innovative CAR T-cell therapies

We are a biopharmaceutical company with operations in China and the U.S. focused on innovative CAR T-cell therapies for the treatment of hematological malignancies and solid tumors.

Read More
About CARsgen<sup>®</sup>
Pipeline
Pipeline
Innovative and differentiated product pipeline

We develop innovative CAR-T technologies to empower the next generation pipeline products.

Read More
We have built an integrated cell therapy platform
<p>CycloCAR<sup>®</sup></p>

CycloCAR®

Cytokine and Chemokine Loaded CAR
<p>THANK-uCAR<sup>®</sup></p>

THANK-uCAR®

Allogeneic CAR-T platform
<p>LADAR<sup>®</sup></p>

LADAR®

Local Action Driven by Artificial Receptor
News Center
2024-11-06
CARsgen® to Present Zevor-cel, CT071 and CT0590 at ASH 2024 Annual Congress
2024-11-01
CARsgen® U.S. Clinical Holds Lifted by FDA
2024-10-09
CARsgen® Submitted Application to Request Lifting Clinical Holds to FDA
2024-08-29
CARsgen® Announces 2024 Interim Results
2024-08-19
CARsgen Announces Enrollment Completion in China GC/GEJ Pivotal Phase II Clinical Trial of the First-in-class Claudin18.2 CAR T (Satri-cel)
2024-06-17
CARsgen Presents Phase II Results on Zevorcabtagene Autoleucel and First-in-human CT071 Results at EHA 2024